Zobrazeno 1 - 10
of 880
pro vyhledávání: ''
Publikováno v:
American Journal of Clinical Oncology. 44:519-525
OBJECTIVES The POLO (Pancreas Cancer Olaparib Ongoing) trial demonstrated improvement in progression-free survival (PFS) with olaparib maintenance in advanced pancreatic cancer (APC) patients with germline BRCA1/2 mutations who had disease control af
Autor:
Albert C. Lockhart, Andrea Wang-Gillam, Michael J. Naughton, Joel Picus, Rama Suresh, Feng Gao, Gretel Terrero, Maria Q. Baggstrom, Lauren Trull, Cynthia Ma, Paula M. Fracasso, Benjamin R. Tan, Manik Amin, Stephanie Belanger
Publikováno v:
American Journal of Clinical Oncology. 44:443-448
Introduction The mammalian target of rapamycin (mTOR) is a downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, and plays a central role in cell proliferation, growth, differentiation, migration, and survival. Temsirolimus
Autor:
Rajneesh Kumar Singh, Koipillai Joseph Maria Das, Shagun Misra, Shaleen Kumar, Shalini Singh, Susheel Kumar Yeshala, Senthil Kumar
Publikováno v:
American Journal of Clinical Oncology. 44:475-481
OBJECTIVES The standard of care for resectable gastric cancers (GCs) includes perioperative chemotherapy (CT) or postoperative chemo/chemoradiotherapy (CRT) strategies. Poor treatment compliance postsurgery suggests that intensified surgical adjuvant
Publikováno v:
American Journal of Clinical Oncology. 44:158-161
Objective The objective of this study was to review real-world patterns of chemotherapy utilization among patients with metastatic gastric/lower esophageal adenocarcinoma with particular focus on the use of ramucirumab plus paclitaxel in previously t
Autor:
Haji Chalchal, Nicholas Chandna, Michael A. J. Moser, John Shaw, Shahid Ahmed, Kamal Haider, Adnan Zaidi, Gopinath Narasimhan
Publikováno v:
American Journal of Clinical Oncology. 44:93-98
Limited evidence is available regarding the survival benefit of second-line therapy in real world patients with advanced biliary tract and gallbladder cancer. Until very recently, there was a lack of randomized clinical trials to address this importa
Autor:
Jennifer Renaud, Rimini Breakstone, Ashlee Sturtevant, Kevin P. Charpentier, Lindsey Cavanaugh, Adam J. Olszewski, Kara L. Leonard, Alexander G Raufi, Howard Safran, Khaldoun Almhanna, Rachel E. Beard, Kelsey MacKinnon
Publikováno v:
American Journal of Clinical Oncology. 43:857-860
Objectives Multiple clinical trials have established a role for adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Adjuvant FOLFIRINOX increases survival as compared with gemcitabine but with increased toxicity. FOLFOX+nab-pacl
Autor:
Erin N. McAndrew, Hanbo Zhang, Pascal Lambert, Rebekah Rittberg, David E. Dawe, Christina A. Kim
Publikováno v:
American journal of clinical oncology. 45(2)
Advanced pancreatic cancer (APC) disproportionately impacts older adults. Randomized trials demonstrate improved overall survival (OS) with combination chemotherapy including 5-fluorouracil, irinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) or nab
Publikováno v:
American journal of clinical oncology. 45(1)
INTRODUCTION In rectal cancer, neoadjuvant chemoradiation (NCRT) is preferred because of toxicity profile, improved resectability and sphincter preservation, although with no impact on overall survival. Pathologic complete response (pCR) to NCRT has
Autor:
Hyo Soung Cha, Jinkook Kim, Jaihwan Kim, Jin-Hyeok Hwang, Jin Won Kim, Sang Myung Woo, Dong Woo Shin, Se Yeol Yang, Jong-Chan Lee, Min Jae Kim, Ji Won Kim, Woojin Lee, Philiip Park
Publikováno v:
American Journal of Clinical Oncology. 43:654-659
Objective By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC). Methods We constructed a web-based
Autor:
Hao Xie, Tanios Bekaii-Saab, Joleen M. Hubbard, Aminah Jatoi, Robert R. McWilliams, John R. Ogden, Jun Yin, Wen Wee Ma, Gloria M. Petersen, Amit Mahipal, Junjia Liu
Publikováno v:
Am J Clin Oncol
OBJECTIVES Survival benefit of combination over single-agent chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC) was demonstrated in younger patients in clinical trials. The authors aimed to evaluate whether this survival benefit of c